Earnings
Blink Charging at H.C. Wainwright conference: shift toward profit
Blink Charging indicated a move toward profitability while speaking at the H.C. Wainwright conference.
AXA Raises Profit Targets, Prioritizes Dividends Over M&A
French insurer AXA raised its EPS growth forecast to 7–9% annually through 2029 and widened its ROE target to 15–17%, saying high payouts will take priority over acquisitions.
Chapel Down to Report Interim Results on Sept 23
The UK vineyard operator will publish half-year figures for the period ending June 30 and hold an investor presentation at 12:30 pm BST on Sept 23.
Kistos reports $205m pro-forma H1 EBITDA, completes Oman Blocks 3&4 deal
Kistos said pro-forma H1 2026 EBITDA was about $205m and actual EBITDA $154m, after completing a 20% interest in Oman Blocks 3&4 and refinancing debt.
PMV Pharma at H.C. Wainwright: rezafapt nears pivotal test
PMV Pharma highlighted that its rezafapt candidate is approaching a pivotal test during an H.C. Wainwright briefing.
Inditex to Report H1 Results; Apple Holds Product Event on Sept. 9
Inditex releases half-year figures and Apple hosts a product launch, while central banks in Hungary and Poland announce rate decisions alongside U.S. ADP job data.
Palo Alto Networks shares fall after weak outlook offsets earnings beat
Cybersecurity maker missed on guiding a sequential revenue drop for Q1 despite reporting Q4 results that topped consensus estimates.
Earnings call transcript: New Hope Group lifts output and dividend in H2 2026
Finance Review Daily is tracking this developing story; further verified details were not immediately available.
17EdTech posts first quarterly GAAP profit in Q2 2026 as revenue jumps 254.6%
Net revenues rose to RMB 90.1 million, gross margin reached 69.2%, and the company approved a $10 million share repurchase. Shares gained 29.8% in regular trading and 19.5% after hours.
Dave & Buster's Q2 Loss Misses Estimates, Shares Plunge After Hours
Dave & Buster's reported an adjusted loss of $0.27 per share versus expected profit, while revenue slipped 2.4%. Shares fell 12.5% in after-hours trading.
Evertz misses EPS despite 5.5% sales growth in Q1 fiscal 2027
Media tech company posts CAD 118.3M in revenue and a CAD 289M backlog surge, but diluted EPS of CAD 0.10 fell well short of the CAD 0.1433 consensus.
Sobi lifts 2026 guidance after 29% Q2 growth and product progress
Sobi raised full-year 2026 revenue and earnings guidance after 29% second-quarter growth, while outlining timelines for ALTUVOCT, Tryngolza, Aspaveli and NASP.
MindWalk Holdings Revenue Jumps 21%, Net Loss Widens in Q1 2027
The Canadian AI drug‑discovery firm reported revenue of CAD 3.8 million, up 21% year‑over‑year, while net loss from continuing operations expanded nearly 50% as sales and marketing spending surged.
Radiant Logistics Q4 Earnings Top Estimates, Shares Jump 6.8%
The trucking and logistics company reported fourth-quarter results that exceeded Wall Street expectations, with diluted EPS of $0.15 against a $0.06 consensus and revenue up 18.5%. Shares rose 6.83% in after-hours trading.
Emergent BioSolutions cuts debt to $515M, raises EBITDA at Wainwright conference
Emergent BioSolutions said gross debt fell to $515 million from about $800 million, while adjusted EBITDA rose to $132 million and year-to-date revenue reached $390 million.
Agilon Health Says Turnaround Gains Ground as 2026 EBITDA Guidance Rises
CFO Jeff Schwaneke outlined raised 2026 EBITDA guidance, improved cash, cost-trend progress and Medicare Advantage contracting details at Jefferies' healthcare conference.
Intellia outlines HAE launch plan, $630M cash runway ahead of lonvo-z vote
Intellia Therapeutics detailed its commercial strategy for CRISPR therapy lonvo-z, citing $630 million in cash and a runway into 2028, as the FDA's PDUFA date approaches.
Kairos Pharma Focuses on Drug Resistance Strategy at H.C. Wainwright Conference
Kairos Pharma presented its resistance strategy at the H.C. Wainwright conference, highlighting its lead antibody ENV105 and clinical trial progress.
Novocure Projects EBITDA Breakeven by Year-End as Lung Cancer Franchise Expands
The cancer-treatment device maker reported $699M in trailing revenue with 11% growth and outlined a path to adjusted EBITDA breakeven by late 2025 at the Morgan Stanley healthcare conference.
Fuel Tech CEO outlines growth strategy, targets $27M revenue and $20M backlog
At the H.C. Wainwright conference, Fuel Tech President and CEO Ramesh Nuggihalli said the board’s sole mandate is growth, projecting full‑year revenue above $26.5 million and a backlog near $20 million.
Insmed Raises Revenue Guidance for BRINSUPRI and TPIP at Morgan Stanley Conference
Insmed CEO Will Lewis presents updated financial projections for BRINSUPRI and TPIP, highlighting strong launch momentum and future growth potential.
KeyCorp Maintains Full-Year Guidance on NII, Margin, Loan Growth
KeyCorp CFO said the bank expects 9%–11% NII growth, 3%–3.05% core NIM in 2026, and 4.5%–5% overall loan growth, with investment banking fee guidance raised.
East West Bank Targets Fee Growth and Capital Returns at Barclays Conference
The bank cited 17% ROTCE, low-cost deposit gains, and a new RIA platform as growth drivers while highlighting tariff-related flows and selective CRE activity.
Yesway outlines fuel, food, growth at Goldman Sachs conference
The No. 15 U.S. convenience-store operator posted $2.99 billion in trailing revenue and a 22% growth forecast for fiscal 2026 as it charts an aggressive expansion plan.